Detail akcie Pro Pharmace online

Business Summary: Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 28% to $17.2M. Lower net loss reflects Research and development decrease of 46% to $9.3M (expense), Stock-based Compensation in R&D decrease of 37% to $444K (expense), Other General and administrative decrease of 8% to $2.2M (expense).